Bridging GPRC5D/CD3 antibody with BCMA CAR-T for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests whether giving a bispecific antibody (GPRC5D/CD3) before BCMA CAR-T cell therapy can help people with multiple myeloma that has come back or is not responding to treatment. It aims to improve outcomes for patients who have already tried many other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have multiple myeloma that has come back or is not responding to treatment, and you have tried at least one immunomodulatory drug, one proteasome inhibitor, and one anti-CD38 antibody.
- You must be able to have your blood cells collected for making the CAR-T cells.
- Your liver, kidney, and blood counts are within certain limits.
- You do not have active infections like hepatitis B, C, or HIV.
- You are not pregnant, breastfeeding, or planning to donate sperm during the study and for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a bispecific antibody (BCMA/CD3) given as a short-term treatment before CAR-T cell therapy in people with multiple myeloma that has come back or stopped responding to multiple treatments. The goal is to see if this approach can help control the disease while CAR-T cells are being prepared.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
This trial tests a new kind of immunotherapy that uses your own immune cells, called CAR-T cells, to target two specific markers (BCMA and GPRC5D) found on myeloma cells. It's for people whose multiple myeloma has come back or stopped responding to earlier treatments.
This trial tests a new cell therapy (CAR-T) that targets two proteins on myeloma cells for patients whose cancer has returned or not responded after at least three prior treatments. It aims to see if this therapy is safe and effective.
This trial tests a new kind of immunotherapy called CAR-T that targets BCMA on myeloma cells. It is for people whose multiple myeloma has come back after or not responded to at least two previous treatments.
This trial tests a lab-made immune cell therapy (CAR-T) designed to attack a protein called BCMA on myeloma cells. It’s for adults whose multiple myeloma or related plasma cell disease has come back or didn’t respond to prior treatment, aiming to improve cancer control.
Hear when a new Relapsed/Refractory Multiple Myeloma (RRMM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.